The DOI matches its Crossref record.
Cerebellar toxicity with high-dose cytosine arabinoside.
Abstract
CNS dysfunction, especially impaired cerebellar function, is the dose-limiting toxicity associated with high-dose cytosine arabinoside, which precludes doses of greater than 48 g/m2. Four hundred eighteen patients between the ages of 2 and 74 years with leukemia or lymphoma received 36 to 48 g/m2 cytosine arabinoside either alone or with anthracycline antibiotics, 4'-(9-acridinylamino) methane sulfon-m-anisidine (m-AMSA), or total body irradiation. In only 35 of 418 patients (8%) did severe cerebellar toxicity develop; it was irreversible or fatal in four (1%) patients. The age of the patient was a critical factor in the incidence of severe cerebellar toxicity. Patients greater than 50 years old had a statistically significant greater incidence of cerebellar toxicity compared with younger patients (26/137, 19%, v 9/281, 3%; P less than .0005, chi 2). Neither the diagnosis, disease status, sex, nor the regimen altered the incidence of severe cerebellar toxicity (when corrected for age). A second course of high-dose cytosine arabinoside, administered to 62 patients, did not increase the incidence of severe cerebellar toxicity, which occurred in five (8%) of these patients. Two of the five patients had severe toxicity with the initial course. Of the 60 patients with no antecedent cerebellar dysfunction, three (5%) had severe toxicity with the second course: one of 41 patients were less than 50 years old; two of 19 patients were greater than or equal to 50 years. Since the occurrence of severe cerebellar dysfunction is greatly affected by age, reduced doses of high-dose cytosine arabinoside should be given to patients greater than 50 years old, and methods for reducing the cerebellar toxicity should be investigated in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zittoun, R. A., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501263320403 · Cited by 849
Cognitive deficits in adult patients with brain tumours
Taphoorn, M. J., & Klein, M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00680-5 · Cited by 756
Verstappen, C. C. P., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003) · Drugs · doi:10.2165/00003495-200363150-00003 · Cited by 456
Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Pröschel, M., & Noble, M. (2008) · Journal of Biology · doi:10.1186/jbiol69 · Cited by 316
Cytarabine and neurologic toxicity.
Baker, W. J., Royer, G. L., & Weiss, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.679 · Cited by 285
Metadata
- Authors
- Herzig, R. H., Hines, J. D., Herzig, G. P., Wolff, S. N., Cassileth, P. A., Lazarus, H. M., Adelstein, D. J., Brown, R. A., Coccia, P. F., & Strandjord, S.
- Venue
- Journal of Clinical Oncology
- Published
- 1987-06
- Volume
- 5
- Issue
- 6
- Pages
- 927-932
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1897993962
- Cited by
- 162
- References
- 0
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebellar toxicity with high-dose cytosine arabinoside. https://app.cochat.ai/papers/10.1200/jco.1987.5.6.927
- The paper
- Herzig, R. H., Hines, J. D., Herzig, G. P., Wolff, S. N., Cassileth, P. A., Lazarus, H. M., Adelstein, D. J., Brown, R. A., Coccia, P. F., & Strandjord, S. (1987). Cerebellar toxicity with high-dose cytosine arabinoside. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1987.5.6.927
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.